Trinity Biotech PLC (NASDAQ:TRIB) Stock Short Interest Report for September

Trinity Biotech PLC (NASDAQ:TRIB) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totaling 17,870 shares, an increase of 123.3% from the September 15th total of 8,001 shares. Approximately 2.4% of the company’s shares are sold short. Based on an average trading volume of 8,408 shares, the short-interest ratio is presently 2.1 days.

Trinity Biotech Stock Performance

Shares of Trinity Biotech stock traded down $0.24 during trading on Thursday, hitting $6.37. The company’s stock had a trading volume of 2,481 shares, compared to its average volume of 23,917. The company has a fifty day simple moving average of $8.73 and a two-hundred day simple moving average of $13.77. The company has a market capitalization of $5.16 million, a PE ratio of -0.14 and a beta of 0.73. Trinity Biotech has a 52 week low of $5.01 and a 52 week high of $52.50.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its stake in Trinity Biotech stock. Williams & Novak LLC increased its stake in Trinity Biotech PLC (NASDAQ:TRIB) by 30.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 140,543 shares of the company’s stock after buying an additional 32,900 shares during the period. Williams & Novak LLC owned 3.91% of Trinity Biotech worth $55,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 78.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 4th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Trinity Biotech

Trinity Biotech plc is a biotechnology and medical diagnostics company headquartered in Bray, Ireland. The company develops, manufactures and markets diagnostic products used by clinical laboratories, healthcare professionals and patients.

Its product portfolio includes tests for infectious diseases, autoimmune disorders and diabetes. Trinity Biotech is particularly known for HIV diagnostic products, including rapid and laboratory-based testing solutions, as well as assays and instruments used in clinical testing.